Serum HBV DNA suppression and seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B patients.

被引：0
|
作者：
Heathcote, EJ
Jeffers, L
Perrillo, R
Wright, T
Sherman, M
Gilson, R
Shakil, AO
Namini, H
James, C
Ho, V
Fry, J
Brosgart, CL
机构：
[1] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada
[2] Univ Miami, Miami, FL 33152 USA
[3] Ochsner Clin N 8, New Orleans, LA USA
[4] San Francisco VA Med Ctr, San Francisco, CA USA
[5] Toronto Gen Hosp, Toronto, ON, Canada
[6] Mortimer Market Ctr, London, England
[7] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[8] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
575
引用
收藏
页码：316A / 316A
页数：1
相关论文
共 50 条
  • [41] Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine
    Manalakopoulos, S.
    Bethanis, S.
    Koutsounas, S.
    Goulis, J.
    Vlachogiannakos, J.
    Christias, E.
    Savariadis, A.
    Pavlidis, C.
    Triantos, C.
    Christidou, A.
    Papatheodoridis, G.
    Karamanolis, D.
    Tzourmakliotis, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (03) : 266 - 273
  • [42] Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Marcellin, Patrick
    Chang, Ting-Tsung
    Lim, Seng G. Lee
    Sievert, William
    Tong, Myron
    Arterburn, Sarah
    Borroto-Esoda, Katyna
    Frederick, David
    Rousseau, Franck
    HEPATOLOGY, 2008, 48 (03) : 750 - 758
  • [43] Kushenin combined with adefovir dipivoxil affects the HBV-DNA load in serum, immune functions and liver functions of patients with chronic hepatitis B
    Feng, Jing
    Huang, Jiandong
    Li, Zhiqin
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (06) : 5837 - 5842
  • [44] Hepatitis B virus (HBV) mutations during long-term therapy in chronic hepatitis B patients
    Arrese, E.
    Basaras, M.
    Blanco, S.
    Ruiz, P.
    Cisterna, R.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E233 - E234
  • [45] Long-term HBV kinetics classification during treatment with adefovir dipivoxil
    Neumann, A
    Havlin, Y
    Tal, R
    Tsiang, M
    Wulfsohn, M
    Brosgart, C
    Fry, J
    Gibbs, C
    JOURNAL OF HEPATOLOGY, 2002, 36 : 121 - 121
  • [46] Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B
    Liu, Yan
    Wang, Chunmei
    Zhong, Yanwei
    Chen, Li
    Li, Xiaodong
    Ji, Dong
    Wang, Huifen
    Xin, Shaojie
    Zoulim, Fabien
    Xu, Dongping
    ANTIVIRAL THERAPY, 2010, 15 (08) : 1185 - 1190
  • [47] THE EFFICACY OF TELBIVUDINE IN COMBINATION WITH ADEFOVIR DIPIVOXIL FOR CHRONIC HEPATITIS B PATIENTS WITH POOR RESPONSE TO ADEFOVIR DIPIVOXIL
    Chen, En-Qiang
    Zhou, Tao-You
    Wang, Jin-Rong
    Tang, Hong
    HEPATOLOGY, 2010, 52 (04) : 554A - 554A
  • [48] Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB)
    Locarnini, S
    Qi, X
    Arterburn, S
    Snow, A
    Brosgart, CL
    Currie, G
    Wulfsohn, M
    Miller, MD
    Xiong, S
    JOURNAL OF HEPATOLOGY, 2005, 42 : 17 - 17
  • [49] Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B
    Lee, Jung Min
    Park, Jun Yong
    Kim, Do Young
    Nguyen, Tin
    Hong, Sun Pyo
    Kim, Soo Ok
    Chon, Chae Yoon
    Han, Kwang-Hyub
    Ahn, Sang Hoon
    ANTIVIRAL THERAPY, 2010, 15 (02) : 235 - 241
  • [50] Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy
    Westland, CE
    Yang, H
    Delaney, WE
    Thibault, V
    Benhamou, Y
    Gibbs, CS
    Miller, MD
    Wulfsohn, M
    Sullivan, M
    Fry, J
    Brosgart, CL
    Xiong, S
    JOURNAL OF HEPATOLOGY, 2003, 38 : 182 - 182
12345